Repligen Corporation is a life sciences company focused on the development, production, and commercialization of products used in the process of manufacturing biological drugs. The Company's  bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. Repligen is a manufacturer of Protein A, a critical reagent used to manufacture monoclonal antibody-based therapeutics. The Company also supplies several growth factor products used to increase cell culture productivity in biomanufacturing and has developed and marketed a series of OPUS (Open Platform User Specified) single-use chromatography columns used in the biologics purification process. 

Company Growth (employees)
Type
Public
HQ
Waltham, US
Founded
1981
Size (employees)
236 (est)
Repligen was founded in 1981 and is headquartered in Waltham, US

Repligen Office Locations

Repligen has offices in Waltham and Lund
Waltham, US (HQ)
100 41 Seyon St
Lund, SE
47 Sankt Lars väg

Repligen Data and Metrics

Repligen Financial Metrics

Repligen's revenue was reported to be $30.6 m in Q1, 2017
USD

Revenue (Q1, 2017)

30.6 m

Net income (Q1, 2017)

3.1 m

EBIT (Q1, 2017)

5.7 m

Market capitalization (21-Sep-2017)

1.5 b

Cash (31-Mar-2017)

129.7 m
Repligen's current market capitalization is $1.5 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

68.2 m63.5 m83.5 m104.5 m

Revenue growth, %

(7%)31%25%

R&D expense

7.4 m

General and administrative expense

30.9 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

15.6 m15.3 m20.8 m21.5 m19.8 m30.6 m

R&D expense

1.4 m1.6 m1.6 m1.3 m1.5 m1.5 m1.9 m1.9 m1.7 m

General and administrative expense

4.3 m4.5 m6 m6.2 m6 m7 m8.1 m7.1 m9.2 m

Operating expense total

5.8 m6.1 m7.6 m7.5 m7.4 m8.6 m10 m9 m10.9 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

39.8 m35.4 m54.1 m122.2 m

Accounts Receivable

5.3 m

Inventories

1.2 m2.1 m2.1 m24.7 m

Current Assets

86.4 m80.9 m103.3 m184.2 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

33.8 m35.9 m31.2 m40 m48.1 m53.2 m172.6 m157.7 m129.7 m

Accounts Receivable

394.4 k523.4 k57 k331 k564 k226 k669 k

Inventories

12.8 m13.3 m12.2 m14.3 m15.9 m21.3 m23.2 m24.5 m24 m

Current Assets

73.9 m75.7 m83.5 m93.3 m96.3 m105.2 m217.9 m219.8 m185.8 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(1.6 m)8.2 m9.3 m11.7 m

Depreciation and Amortization

1.3 m4 m4.6 m5.3 m

Accounts Receivable

3.6 m(1.6 m)(3.7 m)(3.2 m)

Inventories

(870.3 k)(860.1 k)(6.1 m)(6.2 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

2.8 m1.5 m2.9 m3.6 m2.5 m1.6 m5.5 m6.7 m3.1 m

Depreciation and Amortization

1.2 m2.5 m3.8 m

Accounts Receivable

394.4 k523.4 k57 k(1.1 m)892 k(3.3 m)669 k

Inventories

12.8 m13.3 m12.2 m14.3 m15.9 m(3.1 m)(5.1 m)(6.5 m)24 m
USDY, 2017

Revenue/Employee

129.6 k

Financial Leverage

1.6 x
Show all financial metrics

Repligen Market Value History

Traffic Overview of Repligen

Repligen Online and Social Media Presence

Repligen Company Life and Culture

You may also be interested in